Nanomedical Diagnostics CEO and CTO to Introduce Electronic Label-Free Assay Based on Field Effect Biosensing Technology at IDTechEx Show

Share Article

Ross Bundy and Dr. Brett Goldsmith will share how AGILE R100 provides small therapeutics companies access to the same data available to large pharma.

Image of Nanomedical Diagnostics CEO, Ross Bundy

Nanomedical Diagnostics CEO, Ross Bundy

With AGILE R100, researchers can gain sensitive real-time kinetic binding data at their bench in less than a day. This enables scientists to take control of their lead optimization, no matter the size of their lab.”

Speaking at the Sensors and Graphene & 2D Materials events on November 16 and 17, the two co-founders of Nanomedical Diagnostics will present the proprietary Field Effect Biosensing (FEB) technology behind AGILE R100, a breakthrough label-free biosensor assay.

Small emerging therapeutics companies evaluate binding affinities to confirm hits and optimize leads. “Surface plasmon resonance (SPR) and Bio-Layer Interferometry (BLI) platforms for kinetic analysis cost well over $150,000, which is out of range for most small biotechs,” explains CEO Ross Bundy. “As a result, biophysical testing is outsourced, which adds time and cost to evaluating hits. With the FEB technology behind AGILE R100, researchers can gain sensitive real-time kinetic binding data at their bench in less than a day. This enables scientists to take control of their lead optimization, no matter the size of their lab.”

AGILE R100 is a benchtop label-free assay built with proprietary FEB technology that enables miniaturization and cost-efficiency. The non-optical technique measures current across a field effect biosensor surface immobilized with capture molecules. Binding that occurs on the surface changes the current that is monitored in real-time, enabling accurate affinity, kinetics, and concentration data.

CTO Dr. Brett Goldsmith underscores additional capabilities FEB brings to drug discovery over traditional SPR and BLI methods. “SPR and BLI struggle with small molecules, high concentrations of analyte, measurement in DMSO, and small sample sizes. Because FEB is a charge-based technique, not an optical one, it has no difficulty measuring small molecules down to 1 Dalton as well as larger molecules. High concentrations and DMSO cause no problems for AGILE R100 because there are no optical limitations. And FEB is a highly-sensitive technology, which enables use of just 10 microliters of sample.”

In addition to IDTechEx, Nanomedical Diagnostics will present AGILE R100 at the American Society for Cell Biology Conference in San Francisco from December 4 through December 6.

AGILE R100 is available for commercial sale, for research use only. For more information, visit http://www.nanomedicaldiagnostics.com.

About Nanomedical Diagnostics

Nanomedical Diagnostics (“Nanomed”) is a biotech company based in San Diego, CA. Nanomed has developed a breakthrough all-electronic assay based on Field Effect Biosensing (FEB) technology that provides real-time, label-free kinetic binding and concentration data. AGILE biosensor chips at the heart of the assay leverage the highly sensitive nanomaterial graphene to unite biology with electronics, delivering the unique ability to sense small molecules with no lower size limit in complex media such as DMSO, and use unprecedentedly small amounts of sample.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Angela Shue
Visit website